Bromocriptine in type 2 diabetes mellitus

Shivaprasad, C; Kalra, Sanjay

doi:10.4103/2230-8210.83058

Cited by 62 publications

(60 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The time needed for 80% of medication to be released (T80%) and percent medication dissolved in 2 min (D2 min) from the formulated films (F2, F11and F12) are listed in the table (8).…”

Section: Effect Of Concentrations Of Selected Polymer (Hpmc E5)mentioning

confidence: 99%

See 1 more Smart Citation

Formulation and in Vitro Evaluation of Bromocriptine Mesylate as Fast Dissolving Oral Film

2018

View full text Add to dashboard Cite

Objective: The aim of this study was to formulate and in vitro evaluate fast dissolving oral film of practically insoluble bromocriptine mesylate to enhance its solubility and to improve its oral bioavailability by avoiding first pass effect as well as to produce an immediate release action of the drug from the film for an efficient management of diabetes mellitus type II in addition to an improvement of the patient compliance to this patientfriendly dosage form. Methods:The films were prepared by the solvent casting method using hydroxypropyl methylcellulose of grades (E3, E5, E15), polyvinyl alcohol (PVA), pectin and gelatin as film-forming polymers in addition to polyethene glycol 400 (PEG400), propylene glycol (PG) and glycerin were used as a plasticizer. Poloxamer 407 was used as a surfactant, sodium saccharin as a sweetening agent, citric acid as a saliva stimulating agent, vanilla as a flavouring agent and crospovidone as a super disintegrant. The prepared films then tested for physical characterization, thickness, weight uniformity, mechanical characteristics (folding endurance, tensile strength, percent elongation and Young's modulus), surface pH, in vitro disintegration time, drug content and an in vitro drug release.Results: Films were found to be satisfactory when evaluated for physical characterization, thickness, weight uniformity, mechanical tests, in vitro disintegration time, folding endurance, drug content and an in vitro drug release. The surface pH of all the films was found to be neutral or minor change. Films in vitro drug release studies were also done using USP dissolution apparatus type II (paddle type). The in vitro drug release profile in the optimized formulation F14 was gave 86.8 % of drug released at 2 min. The optimized formulation F14 was also showed satisfactory pH (6.2±0.2), drug content (99.2±0.5%), the disintegration time of 9.2±0.1 seconds and the time needed for 80% of medication to be released (T80 %) was 1.35 minute. Conclusion:The bromocriptine mesylate fast dissolving oral film was formulated. The given film disintegrates within nine seconds which release the drug rapidly and gives an action.

show abstract

“…The time needed for 80% of medication to be released (T80%) and percent medication dissolved in 2 min (D2 min) from the formulated films (F2, F11and F12) are listed in the table (8).…”

Section: Effect Of Concentrations Of Selected Polymer (Hpmc E5)mentioning

confidence: 99%

“…Bromocriptine mesylate acts centrally as an antidiabetic agent by a novel mechanism and reduces plasma glucose, triglycerides, free Fatty Acid (FFA) levels, and possibly cardiovascular events [8].…”

Section: Introductionmentioning

confidence: 99%

Formulation and in Vitro Evaluation of Bromocriptine Mesylate as Fast Dissolving Oral Film

2018

View full text Add to dashboard Cite

show abstract

“…Ezért alkalmazásuk PCOS-ben is felmerül, még normoprolactinaemiás esetekben is, ha IGT vagy IFG igazolható, de PCOS-re vonatkozóan megbízható kutatási adatok még ezen a terü-leten sem állnak rendelkezésre. A dopaminagonisták profi laktikus alkalmazására vonatkozó további kutatáso-kat PCOS-ben az is indokolja, hogy a bromocriptin alkalmazását az FDA már engedélyezte 2TDM kezelésénél [26].…”

Section: Bromocriptin Cabergolinunclassified

A polycystás ovarium szindróma szövődményeinek prevenciója, kezelése és a kórkép bizonyítékokon alapuló, interdiszciplináris ellátásának fontossága

Gődény

Csenteri

2015

Orvosi Hetilap

View full text Add to dashboard Cite

A polycystás ovarium szindróma a nők leggyakoribb endokrin és anyagcsere-betegsége. A szindróma gyakran társul elhízással, hyperinsulinaemiával, növeli a cukorbetegség, a lipidanyagcsere-zavarok és a cardiovascularis betegségek kockázatát. Tekintettel a kórkép komplex megjelenésére és a terápiás eljárásokban jelenleg tapasztalható jelentős eltérésekre, a betegek gondozásához, az optimális terápia megválasztásához interdiszciplináris, gyermekgyógyász, belgyógyász, nőgyógyász, endokrinológus, bőrgyógyász, pszichológus és onkológus együttműködése és a rendelkezésre álló legmagasabb bizonyítékon alapuló preventív és terápiás technológiák alkalmazása szükséges, amely a diagnosztikus eredményeket és a beteg preferenciáit is fi gyelembe veszi. Ezzel javulna a terápia eredményessége, hatékonysága, a betegek biztonsága, életminősége és várható élettartama. A cikk a rendelkezésre álló legmagasabb bizonyítékok, szisztematikus irodalmi áttekintések és metaanalízisek felhasználásával ismerteti a kórképhez társuló klinikai és anyagcsere-szövődmények megelőzéséhez és terápiájához szükséges bizonyítékokat és a bizonyítékokon alapuló ellátás alapelveit. Orv. Hetil., 2015, 156(50), 2018-2026. Kulcsszavak: PCOS, prevenció, terápia, EBM, interdiszciplináris Prevention and treatment of the complications of polycystic ovarian syndromethe signifi cance of an evidence-based, interdisciplinary managementPolycystic ovary syndrome is the most common hormonal and metabolic disorder likely to affect women. The syndrome is often associated with obesity, hyperinsulinemia and adversely affects endocrine, metabolic, and cardiovascular health. The complex feature of the syndrome requires an interdisciplinary approach to treatment, where cooperation of paediatrician, internist, gynaecologist, endocrinologist, dermatologist, psychologist and oncologist is essential. The prevention and the treatment should be based on the best available evidence. This should include physical examination, laboratory tests for hormones, serum insulin, glucose, lipids, in addition patient's preferences should be considered, too. To maximise health gain of polycystic ovarian syndrome, adequate, effective, effi cient and safe treatment is necessary. This article summarises the highest available evidence provided by meta-analyses and systematic reviews of the prevention of metabolic and cardiovascular complications of the syndrome, and discusses the relevant evidence published in the literature.

show abstract

“…The final effect is insulinresistant glucose intolerant dyslipidemic state. [3] Type 2 diabetes mellitus (T2DM) remains uncontrolled in a large number of patients despite advances in medical treatment. Bromocriptine mesylate is a quick release preparation of bromocriptine, which acts on hypothalamic pathways of glucose metabolism.…”

Section: Pathophysiologymentioning

confidence: 99%